Latest filing published 25 May 2022 for Chemomab Therapeutics Ltd., €1,077.
Filing timeline
BuySaleInsider track record
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Joel Michael Maryles: trading record in brief
Joel Michael Maryles, listed as board member, appears in our data through filings on Chemomab Therapeutics Ltd. shares, published by SEC (Form 4). Over a trading history stretching from 18 March 2022 to 24 May 2022, the count stands at 4 filings.
Every open-market trade on record is a purchase: 4 purchases worth €5,072, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant.
The median purchase comes to €1,511. 4 out of 4 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.
Most recently, on 25 May 2022, the filings show an open-market purchase worth €85 in Chemomab Therapeutics Ltd. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Joel Michael Maryles
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 400 shares@ US$2.8935.6% of flowAmerican Depositary SharesSEC:0001178913-22-002173:0Canonical exit: 22 Aug 2022 (T+90)
- 500 shares@ US$4.3264.4% of flowAmerican Depositary SharesSEC:0001178913-22-001181:0Canonical exit: 16 Jun 2022 (T+90)
2 of 2 declarations
